Nivolumab (NCT04472767)

Name: Nivolumab trial for Hepatocellular Carcinoma (NCT04472767)
Uploaded: 2026-10-31T21:13:50.612Z
Duration: 1 min 14 s
Description: Nivolumab trial for Hepatocellular Carcinoma (NCT04472767). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04472767.

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma: a one-minute explainerNCT044727671 min

Nivolumab trial for Hepatocellular Carcinoma (NCT04472767). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with hepatocellular carcinoma confined to the liver, unsuitable for resection or transplant, with a lesion suitable for chemoembolization. Prior systemic cancer treatment is excluded.

The idea: give ipilimumab/nivolumab, then transarterial chemoembolization, followed by oral cabozantinib and further nivolumab. Cabozantinib blocks signals involved in tumor growth and blood-vessel formation. Up to three chemoembolization procedures are allowed.

This phase 2 study plans 35 patients. Farshid Dayyani leads at UC Irvine’s Chao Family Comprehensive Cancer Center in Orange, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.